Should I buy or sell Astria Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATXS shares. View ATXS analyst ratings or view top-rated stocks .

What is Astria Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 1 year target prices for Astria Therapeutics' shares. Their ATXS share price targets range from $18.00 to $25.00. On average, they predict the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 315.8% from the stock's current price. View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts .

How have ATXS shares performed in 2023?

Astria Therapeutics' stock was trading at $14.89 at the start of the year. Since then, ATXS shares have decreased by 68.1% and is now trading at $4.75. View the best growth stocks for 2023 here .

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ATXS earnings forecast .

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.31. During the same quarter in the prior year, the company posted ($3.36) earnings per share.

When did Astria Therapeutics' stock split?

Shares of Astria Therapeutics reverse split on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.15%), Affinity Asset Advisors LLC (3.57%), Jacobs Levy Equity Management Inc. (0.58%), Stratos Wealth Partners LTD. (0.15%), Connor Clark & Lunn Investment Management Ltd. (0.15%) and Invesco Ltd. (0.09%). Insiders that own company stock include Andrew Komjathy and Perceptive Advisors Llc. View institutional ownership trends .

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Astria Therapeutics Stock Price, News & Analysis (NASDAQ:ATXS)

$4.75

+0.10 (+2.15%)

(As of 12/1/2023 ET)

Compare

Today's Range: $4.51
▼
$4.80
50-Day Range: $4.42
▼
$8.38
52-Week Range: $4.26
▼
$16.28

Volume: 310,194 shs
Average Volume: 193,350 shs
Market Capitalization: $172.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.75

Astria Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 315.8% Upside
$19.75 Price Target
Short Interest: Healthy
1.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.35
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.28) to ($2.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

143rd out of 951 stocks

Pharmaceutical Preparations Industry

51st out of 436 stocks

3.5

Analyst's Opinion

Consensus Rating
Astria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.75, Astria Therapeutics has a forecasted upside of 315.8% from its current price of $4.75.
Amount of Analyst Coverage
Astria Therapeutics has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.99% of the float of Astria Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Astria Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Astria Therapeutics has recently decreased by 12.97%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Astria Therapeutics does not currently pay a dividend.
Dividend Growth
Astria Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATXS.

3.0

News and Social Media Coverage

News Sentiment
Astria Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Astria Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ATXS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Astria Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,995,698.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Astria Therapeutics is held by insiders.
Percentage Held by Institutions
87.85% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Astria Therapeutics are expected to grow in the coming year, from ($2.28) to ($2.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Astria Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Astria Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Astria Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Astria Therapeutics Stock (NASDAQ:ATXS)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

ATXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATXS Stock News Headlines

November 27, 2023 | finance.yahoo.com

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress

November 24, 2023 | benzinga.com

Astria Therapeutics Stock (NASDAQ:ATXS) Earnings Dates and Earning Calls

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 21, 2023 | finance.yahoo.com

Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference

November 16, 2023 | benzinga.com

Astria Therapeutics Stock (NASDAQ:ATXS), Analyst Ratings, Price Targets, Predictions

November 14, 2023 | finance.yahoo.com

Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript

November 13, 2023 | finance.yahoo.com

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments

November 13, 2023 | finance.yahoo.com

Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 12, 2023 | businesswire.com

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 ...

November 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Trevi Therapeutics (TRVI)

November 10, 2023 | markets.businessinsider.com

Astria Therapeutics Presents Potential For STAR-0125 To Prevent HAE

November 10, 2023 | benzinga.com

Earnings Preview For Astria Therapeutics

November 10, 2023 | finance.yahoo.com

Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?

November 10, 2023 | finance.yahoo.com

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

November 3, 2023 | finance.yahoo.com

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

October 30, 2023 | finance.yahoo.com

Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

October 19, 2023 | benzinga.com

Astria Therapeutics Director Trades $7.00M In Company Stock

October 15, 2023 | finance.yahoo.com

Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 60% of the company

October 13, 2023 | markets.businessinsider.com

Expert Ratings for Astria Therapeutics

October 13, 2023 | markets.businessinsider.com

Buy Rating for Astria Therapeutics: Promising Acquisition and Strategic Development Plan for STAR-0310

October 13, 2023 | msn.com

HC Wainwright & Co. Maintains Astria Therapeutics (ATXS) Buy Recommendation

October 12, 2023 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know

October 12, 2023 | markets.businessinsider.com

Astria Therapeutics’ Promising Disruptions: Buy Rating Justified by Novel Therapies and Strategic Acquisitions

October 11, 2023 | markets.businessinsider.com

Astria Enters Into Licensing Deal With Ichnos Sciences For Atopic Dermatitis Treatment

October 11, 2023 | finance.yahoo.com

Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering

October 11, 2023 | msn.com

Astria signs licensing deal with Ichnos Sciences to develop atopic dermatitis treatment

See More Headlines

Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATXS
CUSIP: N/A
CIK: 1454789
Web: www.catabasis.com
Phone: (617) 349-1971
Fax: 617-273-2637
Employees: 45
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $19.75
High Stock Price Target: $25.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +315.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -50.33%
Return on Assets: -25.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.41
Quick Ratio: 20.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.46 per share
Price / Book: 1.93

Miscellaneous

Outstanding Shares: 36,300,000
Free Float: 35,062,000
Market Cap: $172.43 million
Optionable: Not Optionable
Beta: 0.84

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Jill C. Milne Ph.D. (Age 55)
Co-Founder, CEO, President & Director
Comp: $928.52k
Mr. Benjamin S. Harshbarger J.D. (Age 54)
Chief Legal Officer
Comp: $621.91k
Mr. Noah Clauser CPA (Age 49)
CFO & Treasurer
Comp: $508.79k
Ms. Keri McGrail
Senior Vice President of Human Resources
Ms. Andrea L. Matthews
Chief Business Officer
Mr. Andrew A. Komjathy (Age 59)
Chief Commercial Officer
Dr. Christopher J. Morabito M.D. (Age 53)
Chief Medical Officer
Mr. John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings or view top-rated stocks.
What is Astria Therapeutics' stock price target for 2024?: 4 Wall Street research analysts have issued 1 year target prices for Astria Therapeutics' shares. Their ATXS share price targets range from $18.00 to $25.00. On average, they predict the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 315.8% from the stock's current price.
View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts.
How have ATXS shares performed in 2023?: Astria Therapeutics' stock was trading at $14.89 at the start of the year. Since then, ATXS shares have decreased by 68.1% and is now trading at $4.75.
View the best growth stocks for 2023 here.
When is Astria Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ATXS earnings forecast.

How were Astria Therapeutics' earnings last quarter?: Astria Therapeutics, Inc. (NASDAQ:ATXS) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.31. During the same quarter in the prior year, the company posted ($3.36) earnings per share.
When did Astria Therapeutics' stock split?: Shares of Astria Therapeutics reverse split on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
Who are Astria Therapeutics' major shareholders?: Astria Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.15%), Affinity Asset Advisors LLC (3.57%), Jacobs Levy Equity Management Inc. (0.58%), Stratos Wealth Partners LTD. (0.15%), Connor Clark & Lunn Investment Management Ltd. (0.15%) and Invesco Ltd. (0.09%). Insiders that own company stock include Andrew Komjathy and Perceptive Advisors Llc.
View institutional ownership trends.
How do I buy shares of Astria Therapeutics?: Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATXS) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial